Wall Street analyst estimates for Incyte Corporation (INCY): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Consensus price target
$137.67 (+14 % vs price $120.39)
between $104.00 and $157.00 · 13 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $5.9B | $5.9B – $6.0B | $2.98 | 15 |
| 2027E | $6.2B | $6.0B – $6.7B | $8.13 | 16 |
| 2028E | $6.6B | $5.5B – $7.7B | $9.06 | 14 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 23 |
| Hold | 20 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 44 |
| Avg rating (−2 sell to +2 buy) | 0.50 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-09 | $1.89 | ||
| 2026-10-29 | $-3.60 | $-3.93 | +8.4% |
| 2026-07-28 | $3.09 | $2.15 | +43.7% |
| 2026-04-28 | $1.81 | $1.34 | +35.1% |
| 2026-02-10 | $1.80 | $1.90 | -5.3% |
| 2025-10-28 | $2.26 | $1.66 | +36.1% |
| 2025-07-29 | $1.57 | $1.39 | +12.9% |
| 2025-04-29 | $1.16 | $1.01 | +14.9% |
Valuation Ratios
| P/E Ratio | 64.04 |
| Price / Book | 4.34 |
| EV / EBITDA | 24.25 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.54B | $1.88B | $2.16B | $2.67B | $2.99B | $3.39B | $3.70B | $4.24B | $5.14B |
| Cost of Revenue | $58.2M | $79.5M | $94.1M | $114.2M | $131.3M | $151.0M | $207.0M | $255.0M | $312.1M | $372.1M |
| Gross Profit | $1.05B | $1.46B | $1.79B | $2.04B | $2.54B | $2.84B | $3.19B | $3.44B | $3.93B | $4.77B |
| Research & Development | $581.9M | $1.33B | $1.20B | $1.15B | $2.22B | $1.46B | $1.59B | $1.63B | $2.61B | $2.05B |
| Selling, General & Admin | $303.3M | $366.3M | $434.4M | $468.7M | $516.9M | $739.6M | $1.00B | $1.16B | $1.22B | $1.38B |
| Operating Expenses | $902.5M | $1.70B | $1.66B | $1.64B | $2.80B | $2.25B | $2.60B | $2.79B | $3.83B | $3.43B |
| Operating Income | $145.0M | -$243.4M | $129.2M | $402.0M | -$263.7M | $585.8M | $591.6M | $655.4M | $101.3M | $1.34B |
| EBITDA | $204.6M | -$253.2M | $171.9M | $543.2M | -$178.2M | $630.2M | $599.6M | $919.4M | $408.2M | $1.76B |
| Interest Expense | $38.7M | $6.9M | $1.5M | $1.9M | $2.2M | $1.9M | $2.7M | $2.6M | $2.3M | $2.4M |
| Pre-tax Income | $107.4M | -$312.3M | $115.3M | $486.8M | -$232.2M | $570.4M | $529.1M | $834.2M | $316.6M | $1.66B |
| Income Tax | $3.2M | $852,000 | $5.9M | $39.9M | $63.5M | -$378.1M | $188.5M | $236.6M | $284.0M | $377.8M |
| Net Income | $104.2M | -$313.1M | $109.5M | $446.9M | -$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.29B |
| EPS | $0.55 | $-1.53 | $0.52 | $2.08 | $-1.36 | $4.30 | $1.53 | $2.67 | $0.16 | $6.59 |
| EPS (Diluted) | $0.54 | $-1.53 | $0.51 | $2.05 | $-1.36 | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
| Shares Outstanding (Diluted) | 194.1 M | 204.6 M | 215.6 M | 217.7 M | 218.1 M | 222.1 M | 224.0 M | 225.9 M | 210.5 M | 200.7 M |
Price
| Price | $120.39 (closing price, October 30, 2026) |
| Market Cap | $24.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: REGN · GMAB · EXEL · LGND · LEGN · NRIX
Explore sector: Healthcare · Biotechnology
More sections of INCY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks